CAR T Cell Therapy Market By Targeted Antigen, By Application, Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Hepatocellular Carcinoma

Credence Research Logo
Market assessment is a comprehensive tool which gives useful insights regarding the existing business environment in the development of CAR T cells and its useful application in the treatment of cancer.

The latest market report published by Credence Research, Inc. “CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2018 to 2026.

Market Insights

One of the most promising areas of cancer research and treatment is known as immunotherapy, in which a patient’s own immune system is enlisted in the fight against cancer. CAR-T cell therapy is supposed to be an important advancement in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, the rising rate of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were recorded worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, the introduction of new therapies into the market is further expected to bolster the growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders are expected to hinder the growth of the global CAR-T cell therapy market.

Browse the full report CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at http://www.credenceresearch.com/report/car-t-cell-therapy-market

The diagnosis of acute lymphocytic leukemia (ALL) is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. Due to technological advancement in the diagnostic kits acute lymphocytic lymphoma can be detected early and effective treatment can be started immediately. Flow cytometry and immunohistochemistry are useful in identifying the immunophenotyping by the proteins expressed by the cells. It is useful in determining the exact type of leukemia. Chromosome testing is being widely employed for the precise diagnosis of acute lymphocytic leukemia to accurately identify the DNA translocation between chromosome 9 and chromosome 22. World Health organization guidelines have postulated that acute lymphocytic leukemia can be prevented upto a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of ALL was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. CAR T cell therapy is the most hot topic discussed among oncologist throughout the globe. The FDA approved CAR T cell therapy are Axicabtagene ciloleucel (Yescarta), Tisagenleucel (Kymriah), and Tocilizumab (Actemra). During the clinical trial studies few side effects have been encountered in patients put on CAR T cell therapy are cytokine release syndrome, b-cell aplasia and tumor lysis syndrome.  

Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. CD 22 and CD 30 antigens show promising result in preclinical trials for the treatment of non-Hodgkin’s lymphoma.

Recent approval of CD19 antigens as CAR T cell therapy for the treatment of b cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL.  Non-Hodgkin’s lymphoma and multiple myeloma are being diligently studied by pharmaceutical players owing to their rising prevalence and lack of efficacy utilizing chemotherapy.

Rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the North America CAR T cells therapy market. Moreover the domicile of pharmaceutical companies pioneering in CAR T cell therapy. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the positive growth of CAR T cell therapy in Asia Pacific.

The major pharmaceutical players actively engaged in the CAR T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.

CD19-targeted CAR T cells herald a new era and model shift in cancer treatment.

The potential for Kymriah and Yescarta to cure selected pediatric and young adult patients with acute lymphoblastic leukemia or adults with aggressive B-cell lymphoma is bringing a new hope for those who earlier exhausted all therapy options.

The landmark approvals of Kymriah and Yescarta have spurred unprecedented development in this field. The possibility of bringing a ground-breaking treatment to market has sparked a wave of investment and innovation from pharma companies from around the globe.

CAR T cells are the fastest advancing technology in oncology right now, and what is on the market today could be quickly superseded by next generation treatments tomorrow. These will be therapies that address current uptake challenges through better in efficacy, safety, and delivery mechanisms.

In the charts below, DRG’s Oncology experts provide a view of where the market is heading and which companies are leading the charge.

Key Market Movements:

  • Rising prevalence of patients suffering with relapsed b cell acute lymphocytic leukemia
  • Proactive role adopted by regulatory agencies for the expedited approval of CAR T cell therapy
  • Promising pipeline for CAR T cell therapy focusing on CD22, CD30 antigens for the treatment of non-Hodgkin’s lymphoma and acute myeloid leukemia respectively

Browse the full report CAR T Cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at http://www.credenceresearch.com/report/car-t-cell-therapy-market

ToC:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global CAR T Cell Therapy Market Portraiture
2.1.1. Global CAR T Cell Therapy Market, by Targeted Antigen, 2017 (US$ Mn)
2.1.2. Global CAR T Cell Therapy Market, by Application, 2017 (US$ Mn)
2.1.3. Global CAR T Cell Therapy Market, by Geography, 2017 (US$ Mn)

Chapter 3. CAR T Cell Therapy Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global CAR T Cell Therapy Market, 2016-2026 (US$ Mn)
3.7. Competitive Landscape : Global CAR T Cell Therapy Market, by Key Players, 2016-2026 (US$ Mn)

Chapter 4. Global CAR T Cell Therapy Market, by Targeted Antigen, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. CD 19
4.3. CD 20
4.4. CD 22
4.5. CD 30
4.6. CD 33
4.7. GD 2
4.8. HER 1
4.9. HER 2
4.10. MESO
4.11. EGFRVLL….

Request Sample: https://www.credenceresearch.com/sample-request/58970

Media Contact
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: +1-800-361-8290
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
State: California
Country: United States
Website: http://www.credenceresearch.com/report/car-t-cell-therapy-market